Hot Links >>


Conference >>


For Participants >>



Prof. Limin Chen
Chinese Academy of Medical Sciences, China
Precision medicine applied in HCV treatment
Hepatitis C Virus (HCV) infects 170 million people worldwide. Up to 85% will develop into chronic infections. Numerous achievements have been made in the field of HCV research, especially in the development of novel treatment regimen that specifically target HCV protease and polymerase . We idenified an 18-gene response signature that can be used to predict whether a given patient will respond to the interferon-based therapy or not with an accuracy of 96%. Other predicting tools such as IL28B SNP will also be discussed in the talk. All these prognostic tools will benefit personalized and precision medicine for the treatment of patients chronically infected with HCV.
Dr. Limin Chen, a professor with Chinese Academy of Medical Sciences (CAMS)/Peking Union Medical College (PUMC) and also an affiliated scientist with the University of Toronto, now is the director and chief scientific officer of the center for transfusion transmitted infectious diseases, Institute of Blood Transfusion (IBT), CAMS/PUMC, Member of the American Association for Studies of Liver Diseases (AASLD) and Canadian Association for Studies of Liver (CASL). He got his MD, MSc in biochemistry and molecular biology in China, PhD in molecular genetics at the University of Toronto. Dr. Chen obtained his postdoctoral training both at the Merck Research Laboratories and at the Harvard Medical School . Currently Dr. Chen’s research focuses on the virus-host interaction of the hepatitis viruses, especially HCV and HBV. He pioneered the work on identification of the response signature and proposed a novel mechanism on how HCV exploits host innate immune response to benefit its persistent infection and resistance to interferon-based therapy.
Home | About Engii | Contact Us
Copyright © 2007 - 2017 Engineering Information Institute. All rights reserved.